M. Wood

发表

Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.

S. Bromidge, S. Dabbs, D. Davies, 1998, Journal of medicinal chemistry.

GABAB2 Is Essential for G-Protein Coupling of the GABAB Receptor Heterodimer

D. A. Brown, R. Russell, M. Pangalos, 2001, The Journal of Neuroscience.

BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties

F. King, T. Blackburn, G. Kennett, 1993, Psychopharmacology.

Critical assessment of noradrenaline uptake in synaptosomal preparations

M. Wood, M. Wyllie, 1983, Naunyn-Schmiedeberg's Archives of Pharmacology.

Gabapentin is not a GABAB receptor agonist

M. Pangalos, M. Wood, Jon T. Brown, 2001, Neuropharmacology.

SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist

A. Brown, D. Middlemiss, S. Bromidge, 1997, Neuropharmacology.

Stereoselective Interaction of Mianserin with 5‐HT3 Receptors

N. Newberry, M. Wood, D. Thomas, 1993, The Journal of pharmacy and pharmacology.

A comparison of the effects of the selective 5-HT uptake inhibitor Wy 27587 on 5-HT uptake into platelets and synaptosomes in the rat

M. Minchin, M. Wood, A. Billingsley, 1989, Neuropharmacology.

Examination of the relationship between the uptake site for 5-hydroxytryptamine and the high affinity binding site for [3H]imipramine II The role of sodium ions

M. Wood, 1987, Neuropharmacology.

Is there a common, high-affinity opioid binding site in rat brain?

M. Wood, M. Wyllie, A. Broadhurst, 1986, Journal of receptor research.

Examination of the relationship between the uptake system for 5-hydroxytryptamine and the high-affinity [3H]imipramine binding site—I Inhibition by drugs

M. Wood, M. Wyllie, A. Broadhurst, 1986, Neuropharmacology.

Assessment of Noradrenaline and 5‐Hydroxytryptamine Uptake in Intact Rat Brain

M. Wood, M. Wyllie, P. Moser, 1985, Journal of neurochemistry.

Panuramine, a selective inhibitor of uptake of 5-hydroxytryptamine in the brain of the rat

M. Wood, M. Wyllie, A. Broadhurst, 1984, Neuropharmacology.

5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.

I. Forbes, P. Ham, T. Blackburn, 1995, Journal of medicinal chemistry.

Synthesis, Biological Activity, and Molecular Modeling Studies of Selective 5‐HT2C/2B Receptor Antagonists.

Frank E. Blaney, S. Dabbs, D. Duckworth, 1997 .

Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists.

S. Dabbs, D. Duckworth, I. Forbes, 1996, Journal of medicinal chemistry.

The C-Terminal Domains of the GABAB Receptor Subunits Mediate Intracellular Trafficking But Are Not Required for Receptor Signaling

R. Russell, M. Pangalos, S. Moss, 2001, The Journal of Neuroscience.

Pharmacological characterisation of human 5-HT2 receptor subtypes.

D. Middlemiss, M. Wood, D. Smart, 2001, European journal of pharmacology.

Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor.

M. Wood, D. Thomas, P. Atkinson, 2000, European journal of pharmacology.

The human GABAB1b and GABAB2 heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen

S. J. Taylor, M. Pangalos, N. Elshourbagy, 2000, British journal of pharmacology.

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry

D. Middlemiss, M. Wood, J. Watson, 1999, British journal of pharmacology.

1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists

J. Hagan, A. Schwarz, A. Capelli, 2007 .

Heterogeneous 3H-rauwolscine binding sites in rat cortex: two alpha 2-adrenoceptor subtypes or an additional non-adrenergic interaction?

M. Wood, A. Broadhurst, B. S. Alexander, 1988, Life sciences.

Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.

G. Tedesco, M. Wood, D. Donati, 2007, Bioorganic & medicinal chemistry letters.

Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

M. Wood, Z. Sands, M. Gillard, 2018, Epilepsia.

Contrasting Effects of Allosteric and Orthosteric Agonists on M1 Muscarinic Acetylcholine Receptor Internalization and Down-regulation

C. Langmead, M. Wood, R. Challiss, 2009, Journal of Pharmacology and Experimental Therapeutics.

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.

D. Middlemiss, S. Lightowler, S. Bromidge, 2000, Journal of medicinal chemistry.

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays

M. Wood, R. Kaminski, M. Gillard, 2013, British journal of pharmacology.

Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor

Arthur Christopoulos, Patrick M. Sexton, Christopher J. Langmead, 2010, Molecular Pharmacology.

A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.

S. Bromidge, F. King, G. Riley, 2005, Bioorganic & medicinal chemistry letters.

Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist

T. Ceska, T. S. Kobilka, B. Kobilka, 2021, Nature Communications.

Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor

M. Wood, R. Kaminski, M. Gillard, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

M. Wood, M. Gillard, 2017, Epilepsia.

Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol O-Methyltransferase

J. Barrow, M. Wood, D. Swinnen, 2019, ACS medicinal chemistry letters.

Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.

J. Barrow, M. Wood, D. Swinnen, 2018, Journal of medicinal chemistry.

Unraveling the mechanism and the risk behind seizure liability of lead compounds in a neuroscience project.

M. Wood, S. Authier, Y. Lamberty, 2020, Journal of pharmacological and toxicological methods.

Subcellular Site of Action of Imipramine in Rodent Brain

M. Wood, M. Wyllie, 1986, Journal of neurochemistry.

Modulation of central noradrenaline release by postsynaptic receptors

M. Wood, M. Wyllie, J. Pheysey, 1982, The Journal of pharmacy and pharmacology.

Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.

G. Macdonald, K. Thewlis, G. Riley, 2001, Bioorganic & Medicinal Chemistry Letters.

Discovery of a small molecule modulator of the Kv1.1/Kvβ1 channel complex that reduces neuronal excitability and in vitro epileptiform activity

M. Wood, D. Swinnen, Z. Sands, 2018, CNS neuroscience & therapeutics.

γ‐Aminobutyric AcidA Receptor Function Is Desensitised in Rat Cultured Cerebellar Granule Cells Following Chronic Flunitrazepam Treatment

M. Wood, M. Coldwell, M. J. Brown, 1998, Journal of neurochemistry.

6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.

F E Blaney, S. Bromidge, I. Forbes, 1997, Journal of medicinal chemistry.

Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket

T. Ceska, T. S. Kobilka, B. Kobilka, 2017, Proceedings of the National Academy of Sciences.

Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT 2C 2B receptor function

S. Lightowler, T. Blackburn, G. Kennett, 1994, Neuropharmacology.

In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist

I. Forbes, T. Blackburn, G. Kennett, 1994, British journal of pharmacology.

Detergent-free extraction of a functional low-expressing GPCR from a human cell line.

M. Wood, A. Watts, Richard J. Taylor, 2019, Biochimica et biophysica acta. Biomembranes.

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

D. Middlemiss, S. Lightowler, S. Bromidge, 2001, Neuropharmacology.

Pharmacological Assessment of M1 Muscarinic Acetylcholine Receptor-Gq/11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue

C. Davies, J. Hagan, M. Wood, 2008, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological Assessment of M 1 Muscarinic Acetylcholine Receptor-Gq / 11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue

C. Davies, J. Hagan, M. Wood, 2008 .

Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.

G. Tedesco, G. Riley, M. Wood, 2006, Bioorganic & medicinal chemistry letters.

G Protein Coupling and Signaling Pathway Activation by M1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists

C. Langmead, M. Wood, R. Challiss, 2008, Journal of Pharmacology and Experimental Therapeutics.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

M. Wood, Y. Lamberty, R. Kaminski, 2016, Epilepsia.

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, The Journal of pharmacology and experimental therapeutics.

Site-specific splice variation of the human P2X4 receptor

Robert Davis, M. Wood, G. Sanger, 1999, Neuroscience Letters.

Aripiprazole acts as a selective dopamine D2 receptor partial agonist

M. Wood, C. Reavill, 2007, Expert opinion on investigational drugs.

Identification of Multiple Binding Sites for [3H]5‐Hydroxytryptamine in the Rat CNS

M. Wood, P. Blurton, 1986, Journal of neurochemistry.

Changes in Central 5-Hydroxytryptamine Turnover Induced by Acute and Chronic Inhibition of the Re-Uptake Process

M. Wood, M. Wyllie, G. Diggory, 1981 .

INDUCED BY ACUTE AND CHRONIC INHIBITION OF THE

M. Wood, M. Wyllie, G. Diggory, 1981 .

Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain

Richard E Carson, Marc Laruelle, Shu-Fei Lin, 2016, The Journal of Nuclear Medicine.

In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor

M. Wood, R. Barnaby, V. André, 2016, Molecular Pharmacology.

Therapeutic potential of serotonin antagonists in depressive disorders

M. Wood, J. Watson, Jeannette M Watson, 2002, Expert opinion on investigational drugs.

Studies towards the identification of a new generation of atypical antipsychotic agents.

C. Scorer, J. Hagan, I. Forbes, 2007, Bioorganic & medicinal chemistry letters.

Development of an HTRF Assay for the Detection and Characterization of Inhibitors of Catechol-O-Methyltransferase

J. Barrow, M. Wood, M. Gillard, 2016, Journal of biomolecular screening.

In Vitro and In Vivo Characterization of the Non-peptide NK3 Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia

C. Davies, J. Hagan, J. Kew, 2008, Neuropsychopharmacology.

Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?

M. Wood, 2005 .

Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.

M. Wood, P. Wren, 2008, Progress in brain research.

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1

M. Whittington, C. Langmead, C. Davies, 2008, British journal of pharmacology.

Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist

C. Langmead, A. Christopoulos, I. Forbes, 2006, Molecular Pharmacology.

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.

C. Davies, C. Scott, G. Riley, 2006, CNS & neurological disorders drug targets.

Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors

C. Langmead, P. Sexton, A. Christopoulos, 2007, Molecular Pharmacology.

Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors

M. Wood, V. Dubois, M. Gillard, 2015, British journal of pharmacology.

In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties

I. Forbes, P. Ham, T. Blackburn, 1996, British journal of pharmacology.

Stereoselective blockade of central [3H]5‐hydroxytryptamine binding to multiple sites (5‐HT1A, 5‐HT1B and 5‐HT1C) by mianserin and propranolol

M. Wood, Beverley S. Alexander, 1987, The Journal of pharmacy and pharmacology.

Additional evidence for functional subclassification of alpha-2 adrenoceptors based on a new selective antagonist, SK&F 104856.

J. Hieble, T. Blackburn, M. Wood, 1991, The Journal of pharmacology and experimental therapeutics.

5‐HT2C receptor antagonists: Potential in schizophrenia

Christian A. Heidbreder, D. Middlemiss, M. Wood, 2001 .

Evaluation of 18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain

A. Luxen, J. Aerts, E. Salmon, 2014, The Journal of Nuclear Medicine.

Evaluation of 18 F-UCBH as a Novel PET Tracer for Synaptic Vesicle Protein 2 A in the Brain

E. Salmon, G. Warnock, M. Bahri, 2014 .

Differential Effects of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-Hydroxytryptamine2C Receptor-Mediated Responses

U. Spampinato, M. Wood, S. Navailles, 2006, Journal of Pharmacology and Experimental Therapeutics.

Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.

C. Davies, C. Scott, I. Forbes, 2006, European journal of pharmacology.

The rapid preparation of synaptosomes, using a vertical rotor.

M. Wood, M. Wyllie, 1981, Journal of Neurochemistry.

Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, Journal of medicinal chemistry.

Resolution of monoamine uptake into binding and translocation components

M. Wood, M. Wyllie, 1982, Neuropharmacology.

m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor.

A. Brown, V. Holland, M. Wood, 1996, Neuroreport.

Chronic administration of haloperidol and clozapine induces differential effects on the expression of Arc and c-Fos in rat brain

M. Wood, J. Elliott, Cheryl M Collins, 2014, Journal of psychopharmacology.

Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors

M. Wood, P. Strange, C. Newton, 2016, PloS one.

Structure-Function Studies of Allosteric Agonism at M 2 Muscarinic Acetylcholine Receptors

C. Langmead, P. Sexton, A. Christopoulos, 2007 .

Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor.

G. Riley, M. Wood, K. Y. Avenell, 2000, European journal of pharmacology.

[3H]8‐OH‐DPAT labels the 5‐Hydroxytryptamine uptake recognition site and the 5‐HT1A binding site in the rat striatum

M. Wood, Beverley S. Alexander, 1988, The Journal of pharmacy and pharmacology.

Functional characterization of the antiepileptic drug candidate, padsevonil, on GABAA receptors.

M. Wood, R. Kaminski, P. Ghisdal, 2020 .

In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor s

M. Wood, R. Barnaby, V. André, 2016 .

In-vitro and in-vivo identification of novel positive allosteric modulators of the human dopamine D 2 and D 3 receptor

M. Wood, R. Barnaby, V. André, 2015 .

Model studies on a synthetically facile series of N-substituted phenyl-N'-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT(2C/2B) receptor antagonists.

S. Bromidge, S. Dabbs, D. Davies, 1999, Bioorganic & medicinal chemistry.

N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist.

P. Ham, G. Kennett, M. Wood, 1993, Journal of medicinal chemistry.

Monoamine receptor binding profile of the 5 ht 1a antagonist spiroxatrine

M. Wood, B. S. Alexander, 1987 .

Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders.

M. Wood, 2003, Current drug targets. CNS and neurological disorders.

Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

J. Hagan, G. Macdonald, D. Middlemiss, 2003, Journal of medicinal chemistry.

Antagonist Affinity Estimates from Radioligand Binding and Functional Studies Vary at the Cloned Human 5-HT2C Receptor

V. Holland, M. Wood, David R. Thomas, 1997 .

5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.

G. Tedesco, M. Wood, D. Donati, 2007, Bioorganic & medicinal chemistry letters.